Exposure to environmental and occupational poisons has adverse effects on human health. Chelation therapy is the only way to remove toxic metals from human organs and tissues, and is designed to treat damage associated with acute and / or chronic poisoning. This paper reviews the latest evidence of the successful application of EDTA. The therapeutic effect of ethylenediamine tetraacetic acid (EDTA) on acute and chronic toxic metal load, and the clinical significance of other toxic metal chelators and iron chelators.
Effect of environmental pollution on metal intake: Toxic metals can cause many adverse effects on human health. Individuals may be exposed to toxic metals in the environment through a variety of ways, such as inhalation of air pollution into the respiratory tract , or ingestion of contaminated food and water into the mouth . Environmental exposure is a health risk for the general population and, more specifically, for some professional categories.
High risk workers
Toxicity related to geographical area
Impact on pregnancy and children
Effects on organs and systems
Effects on cells
Considering the serious damage to human health caused by toxic metal exposure, we should study how to determine this kind of pollution in human body?
Target organs / devices, sources and toxicity levels of each toxic metal: kidney, central nervous system, liver, gastrointestinal system, respiratory system, skin, cardiovascular / hematopoietic system, oral / nasal mucosa, musculoskeletal system.
Calcification refers to the deposition of calcium into the neointima (atherosclerotic plaque) and / or media (middle smooth muscle layer) of blood vessels, which can be associated with atherosclerosis, chronic kidney disease, diabetes and other diseases. Vascular calcification leads to arteriosclerosis and affects the stability of atherosclerotic plaque.
Scientist Home Chelation Study (removing calcium crystals and heavy metals)
May be suitable for multidisciplinary rehabilitation:
This product is a nutritional supplement and cannot replace medicine.
If there is any discomfort, it is recommended to stop taking it.
People who have heart or kidney failure should not have chelation therapy at any dose.
If you do not understand the cause of the problem or the problem persists, please consult your doctor as soon as possible
Safety: EDTA calcium disodium has been approved by the food and Drug Administration (FDA) for chelation therapy, which can remove heavy metals from the body. According to the University of Maryland Medical Center, side effects of chelating with calcium disodium EDTA include malabsorption or low levels of various vitamins, including vitamin C and various B vitamins. To help fight low vitamin levels, calcium disodium EDTA is usually taken separately from vitamins on the same day. Other side effects include allergic reactions, dangerous hypoglycemia, blood pressure or calcium levels, renal failure, and seizures.
Side effects: if you feel you may faint, or have severe blisters, peeling, or red rashes, please stop taking this product and tell your doctor that you have taken calcium disodium EDTA. Mild side effects include nausea, vomiting, diarrhea, numbness or tingling (especially around the mouth), headache, pain, redness or acupuncture.
Risk: EDTA calcium disodium is safe in small doses in prescription drugs, eye drops and food preservatives. However, it can cause cramps, nausea, vomiting, diarrhea, headache, hypotension, skin allergy and fever. It's not safe to eat more than 3 grams a day. Too much can lead to kidney damage, low calcium levels, and even death.
Major Ingredients: Oxiglutatione, GSSG, EDTA Ca Na2, Sauredesphytins, Phytic Acid, Phyticacidsolution, Dambos, Cyclohexanehexyl Hexaphosphate.
參考研究報告 / Refs：
1. Grases F, Perelló J, Prieto RM, Simonet BM, Torres JJ (2004). Dietary myo-inositol hexaphosphate prevents dystrophic calcifications in soft tissues: a pilot study in Wistar rats. Life Sci. 75(1):11-9.1.
2. Grases F, Prieto RM, Simonet BM, March JG (2000). Phytate prevents tissue calcifications in female rats. Biofactors. 11(3):171-7.
3. Grases F, Perelló J, Isern B, Prieto RM (2005). Study of a myo-inositol hexaphosphate-based cream to prevent dystrophic calcinosis cutis. Br J Dermatol. 152(5):1022-5.
4. Grases F, Isern B, Perelló J, Sanchis P, Prieto RM (2005). Absorption of myo-inositol hexakisphosphate (InsP6) through the skin: study of the matrix effects mechanism of phytate topical absorption. Front Biosci. 10:799-802.
5. Sun Y, Mauerhan DR, Honeycutt PR, Kneisl JS, Norton HJ, Zinchenko N, Hanley EN Jr, Gruber HE (2010). Calcium deposition in osteoarthritic meniscus and meniscal cell culture. 12(2):R56.
6. Fuerst M, Bertrand J, Lammers L, Dreier R, Echtermeyer F, Nitschke Y, Rutsch F, Schäfer FK, Niggemeyer O, Steinhagen J, Lohmann CH, Pap T, Rüther W (2009). Calcification of articular cartilage in human osteoarthritis. Arthritis Rheum. 60(9):2694-703.
7. Liu YZ, Jackson AP, Cosgrove SD (2009). Contribution of calcium-containing crytals to cartilage degradtion and synovial inflammation in osteoarthritis. Osteoarthritis Cartilage. 17(10):1333-40.
8. Jaovisidha K, Rosenthal AK (2002). Calcium crystals in osteoarthritis. Curr Opin Rheumatol. 14(3):298-302.
9. Chappell LT, Janson M. EDTA chelation therapy in the treatment of vascular disease. J Cardiovasc Nurs. 1996; 10:78-86.
10. Olszewer E, Sabbag FC, Carter JP. A pilot double-blind study of sodium-magnesium EDTA in peripheral vascular disease. J Natl Med Assoc 1990; 82:173-174.
11. Anderson HC1, Mechanisms of pathologic calcification. Rheumatic Diseases Clinics of North America, 01 Aug 1988, 14(2):303-319. PMID: 2845491
26. Effects of glutathione on chromium-induced DNA crosslinking and DNA polymerase arrest. O'Brien T, Xu J, Patierno SRMol Cell Biochem. 2001 Jun; 222(1-2):173-82.
27. Matsumoto ST, Mantovani MS, Malaguttii MIA, Dias AL, Fonseca IC, Marin-Morales MA. Genotoxicity and mutagenicity of water contaminated with tannery effluents, as evaluated by the micronucleus test and comet assay using the fish Oreochromis niloticus and chromosome aberrations in onion root-tips. Genet Mol Biol. 2006;29(1):148–158.
28. Clayton DB. Water pollution at Lowermoore North Cornwall: Report of the Lowermoore incident health advisory committee; Truro: Cornwall District Health Authority; 1989. p. 22.
29. Krewski et al., 2009
30. Aluminium toxicity: its relationship with bone and iron metabolism. Cannata Andía JB Nephrol Dial Transplant. 1996; 11 Suppl 3():69-73.
31. Iron augments stage-I and stage-II tumor promotion in murine skin. Bhasin G, Kauser H, Athar M Cancer Lett. 2002 Sep 26; 183(2):113-22.
32. Iron, free radicals, and oxidative injury. McCord JM Semin Hematol. 1998 Jan; 35(1):5-12.
33. Pathophysiology of iron overload. Hershko C, Link G, Cabantchik I Ann N Y Acad Sci. 1998 Jun 30; 850():191-201.
This product is not registered under the Pharmacy and Poisons Ordinance or the Chinese Medicine Ordinance. Any claim made for it has not been subject to evaluation for such registration. This product is not intended to diagnose, treat or prevent any disease.